SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-022077
Filing Date
2022-08-11
Accepted
2022-08-11 16:10:44
Documents
14
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38563
2 ex99-1.htm EX-99.1 152194
3 ex99-1_1.jpg GRAPHIC 6763
  Complete submission text file 0001493152-22-022077.txt   390535

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lctx-20220811.xsd EX-101.SCH 2968
5 XBRL LABEL FILE lctx-20220811_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE lctx-20220811_pre.xml EX-101.PRE 22365
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3594
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 221155818
SIC: 2836 Biological Products, (No Diagnostic Substances)